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ess: jaew@utas.edu.auSummary According to major asthma management guidelines, long-acting b2-
agonists (LABAs) should be used only when asthma remains symptomatic in patients
already receiving regular inhaled corticosteroids (ICSs). A large Cochrane systematic
review provides evidence that LABAs are safe and beneficial in control of asthma;
sub-group analyses indicating that this is true when ICSs are used and in their
absence. Two other Cochrane systematic reviews have found that LABAs are more
effective than regular short-acting b2-agonists, and are as effective as theophylline
with fewer side-effects. These reviews support guidelines in the use of LABA as
additional therapy when asthma is inadequately controlled by ICS at moderate dose.
However, guidelines may be too conservative, and more studies in stable mild
asthma comparing their use and safety with placebo and ICS are required.
& 2005 Elsevier Ltd. All rights reserved.Introduction
In this paper, we examine the evidence presented
in Cochrane systematic reviews for the effective-
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(J.A.E. Walters).and assess the findings in the context of current
national and international therapeutic manage-
ment guidelines. In particular, we will review the
evidence to support the use of LABA in their current
role in conjunction with inhaled corticosteroid
(ICS).Inhaled b-agonist use
Inhaled b-agonists have been an integral part of
asthma management for the past 50 years. Their
main airway action is through engagement of G-
protein-coupled b-receptors at the surface of
smooth-muscle cells to induce muscle relaxation
and, through that, bronchodilatation. Short-actinged.
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since the 1970s, and have a rapid onset and short
duration of up to 4 h. They are used mainly for
reactive ‘‘relief’’ of symptoms due to bronchocon-
striction, and are effective and safe when used in
this manner. LABAs, available for the past decade,
were designed specifically for regular use, as their
duration of action is at least 12 h. Their intended
use is prospective, to prevent symptoms, whether
spontaneous or due to some environmental or
activity-related airway challenge. They have been
termed ‘‘symptom controllers’’.Inhaled corticosteroid use
The third class of widely used inhaled asthma
medications is corticosteroids, which have disease-
modifying actions through their anti-inflammatory
effects. ICSs have been available since the 1960s,
and have transformed the management of asthma.
The currently accepted clinical wisdom is that, if a
patient needs relatively frequent ‘‘relief’’ medica-
tion, then ICS should be introduced to gain
‘‘control’’ of the disease. The definition of ‘‘fre-
quent’’ varies between management guidelines.1–4
In reality, community-based audits have found that
most asthmatics do not use ICS, even when quite
symptomatic.5Long-acting b2-agonists
Currently, two LABA agents are widely available,
salmeterol and eformoterol. They vary slightly in
mode and length of action, but have clinically
similar effects when used regularly.6,7 Salmeterol is
a partialagonist,8 with slower onset of action, less
total bronchodilator capacity at high dose, and also
less likelihood to develop tachyphylaxis to broncho-
dilatation. Eformoterol is a full agonist,9 with
faster onset of action, greater bronchodilator
efficacy in high dose, but with increased tachyphy-
laxis to smooth muscle relaxation.10 Both LABAs
have been shown to develop tachyphylaxis to their
bronchoprotective actions in inhibiting induced
bronchoconstriction when used regularly at con-
ventional doses, although some degree of protec-
tion remains.11,12
In addition to their bronchodilator action, there
is also evidence that LABAs have an anti-inflamma-
tory and anti-remodelling effect on the airway in
individuals already taking ICS.13,14 One mechanism
may be through enhancing movement of the
corticosteroid–corticosteroid receptor complexfrom the cytoplasm to the nuclear compartment
where it modulates cytokine and other gene
transcription.15,16 The anti-inflammatory action
seems especially evident in decreasing eosinophil
infiltration of the airway wall,13,14 possibly by
stimulating epithelial chemokine release into the
airway lumen, so as to increase luminal cellular
clearance.17Concerns over b2-agonist use
Just at the time LABAs were being introduced,
concerns about regular use of SABAs, the so-called
‘‘b-agonist debate’’, were at its height. A number
of studies had implicated regular and perhaps
excessive use of SABA in (1) asthma deaths and
near-death emergencies;18,19 (2) worse clinical
outcomes;20,21 and (3) induction of increased
degrees of airway reactivity.22,23
These concerns about adverse outcomes with
frequent and regular SABA are likely to have mainly
been related to sub-optimal use of ICS in individuals
whose asthma was inadequately controlled and
treated.24 However, the legacy of this debate led to
an adverse sentiment against b-agonists in general,
just at the time that clinicians needed to come to
terms with the availability of LABAs, specifically
designed and marketed to be used regularly in a 12-
hourly regimen. This may have affected their
subsequent clinical research development and
placement in asthma management guidelines
(Table 1).Asthma management guidelines
In the Global Initiative for Asthma (GINA) guide-
lines,1 which classify asthma by severity, recom-
mendations for medication use are based upon
different levels of disease severity. Their recom-
mendation is to introduce LABA for moderate
persistent asthma, together with regular ICS at
‘‘low to medium’’ dose. The Australian National
Asthma Council guidelines2 also suggest the use of
LABA together with regular ICS in both adults and
children based on disease severity. They recom-
mend considering the addition of LABA to moderate
doses of ICS for moderate disease and their use with
high-dose ICS in severe disease. The BTS/SIGN3
guidelines use a different approach, based on
disease activity. They recommend the addition of
LABA where there is inadequate disease control on
low-dose ICS. The full implementation of current
guidelines remains the challenge for clinicians, yet
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Table 1 International guidelines for long-acting b-agonist treatment in asthma.
GINA1 NAC2 BTS/SIGN3,4
Moderate persistent Moderate: with ICS up to 800 mg/day Inadequate control on low-
dose inhaled steroids
Symptoms daily Symptoms most days The first choice as add-on
therapy to inhaled steroids
in adults and children (5–12
years) is an inhaled LABA
Nocturnal symptoms more than
once a week
Exacerbations o6–8 weeks apart,
which affect day-time activity
and sleep
Inhaled LABA should not be
used without ICS
Daily use of inhaled SABA Exacerbations last several days
FEV1 or PEF 60–80% predicted Occasional emergency department
visit
FEV or PEF variability over 30%
Using low–medium dose ICS
Severe persistent Severe: with ICS up to 2000mg/day
Symptoms daily Persistent
Frequent nocturnal symptoms Limited activity level
Limitation of physical activities Nocturnal symptoms more than once
a week
FEV1 or PEF 60% r predicted Frequent emergency
Frequent exacerbations Department visits and hospital
admission in past year
Using high-dose ICS FEV1 may be significantly reduced
between exacerbations
BTS, British Thoracic Society; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long-acting b2-agonists;
NAC, National Asthma Campaign; SIGN, Scottish Intercollegiate Guidelines Network; PEF, peak expiratory flow.
J.A.E. Walters et al.386more research on the safety and effectiveness of
LABAs at different levels of disease severity
and activity is required. Indeed, in Australia, the
NAC Management Handbook (2002)2 states that
‘‘debate continues as to whether the regular long-
term use of high-dose, SABA causes deterioration in
asthma’’, but concedes, ‘‘concerns about LABAs
have not been clearly demonstrated in studies to
date’’. Nevertheless, the FDAs have sufficient
anxieties about the use of salmeterol to have
issued a ‘‘black box’’ warning on the medicine’s
label.Cochrane systematic reviews of interest
Three Cochrane systematic reviews directly rele-
vant to the use of LABA in asthma have been
published: (1) inhaled LABA for stable chronic
asthma, first published in March 2003;25 (2) regular
treatment with LABA versus daily regular treatment
with SABA in adults and children with stableasthma, first published in January 2003;26 (3) LABA
versus theophylline for maintenance treatment of
asthma, first published in August 1999.27
Three relevant protocols28–30 have also been
registered on the Cochrane Library at the time of
writing in late 2004. These are related to the
combined use of LABA and ICS in asthma, the
potential superiority of the combination against ICS
alone, and the potential superiority of the combi-
nation, if used together, in a single inhaler rather
than in separate inhalers.Inhaled long-acting b2-agonists for stable
chronic asthma
This Cochrane systematic review25 involved 85
studies and over 15,000 patients. Most studies were
parallel-group design, and mainly involved adults
with asthma of mild-to-moderate severity who
were treated for between 6 weeks and 1 year
(Table 2).
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Table 2 Description of studies included in Cochrane reviews of long-acting b-agonist treatment.
LABA compared
with placebo
LABA compared
with regular SABA
LABA compared
with theophyllines
Total number of studies
included
85 31 12
Total number of participants 15,245 32,967 1329
Allocation concealment
Adequate 15 5 1
Unclear 70 26 10
Study design
Parallel group 56 24 7
Crossover 29 7 5
Participants
Adults/adolescents 7 28 12
Children less than 12 years 14 3
Period of treatment
Less than 6 weeks 32 11 7
6–24 weeks 45 19 4
25–52 weeks 8 1 1
Classification of asthma
Mild 12 3
Mild-to-moderate 51 23 1
Severe 11 3
Unknown 11 11
LABA, long-acting b2-agonists; SABA, short-acting b2-agonists.
Long-acting b2-agonists in asthma: an overview of Cochrane systematic reviews 387If the included studies are separated according to
baseline treatment of asthma, then the following
picture emerges: in 33 studies, participants were
taking a variety of regular medications, including
ICS, cromones, oral theophylline or oral corticos-
teroid. The total number of participants was 7927.
The mean number of participants per study was 240
(range 7–614 participants). In these studies, the
use of ICS ranged from 20% – 95%, with 24 studies
having more than 50% of participants on ICS.
In 34 studies, all participants used ICS only as
regular treatment. The number of participants was
5443. The mean number of participants per study
was 143 (range 9–698 participants).
In 21 studies, participants were not allowed to
take ICS. The total number included in these
studies was lower at 1875. The mean number of
participants per study was 89 (range 10–408
participants). The primary outcome of the review
was asthma control (Table 3).
For morning peak expiratory flow (PEF), a
statistically significant difference was found in
favour of regular LABA over placebo, the overall
weighted mean difference (WMD) being 26.8 l/min
(95% CI 20.1–33.2). Sub-group analyses showedsimilar positive treatment differences whether on
regular ICS or not. In children, the difference was
not statistically significant, but only 207 partici-
pants were included in the analysis (Fig. 1).
For evening PEF, again a statistically significant
advantage was found for LABA, the WMD being
19.2 l/min (95% CI 11.6–26.7). Sub-group analyses
showed similar treatment effects in people taking
ICS and those on mixed co-interventions but not in
people taking regular ICS or in children. Trends
were in the same direction for these sub-groups,
but the numbers of participants were small in the
ICS-free studies (n ¼ 79) and in children (n ¼ 207)
(Fig. 1). It is likely that the absence of statistically
significant benefit in the sub-groups is due to small
numbers of participants. Indeed, when assessing
PEF as change from baseline, where larger numbers
of participants were included in the sub-groups of
children and non-ICS users, statistically significant
differences were found (Fig. 2). However, for both
these sub-groups, the WMD was smaller than for the
overall change in either morning or evening PEF.
For FEV1, a statistically significant benefit was
found for LABA, the overall WMD being 180ml (95%
CI 130–230), with similar effects for those on mixed
A
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Table 3 LABA in chronic stable asthma: differences in outcomes for LABA versus placebo.
Outcome Overall Participants not taking ICS
Difference Studies Participants Difference Studies Participants
Morning PEF (l/min) 26.78 (20.36–3.20) 19 4066 49.08 (6.22–91.95) 3 88
Evening PEF (l/min) 19.18 (11.63–6.73) 13 3094 15.58 (–30.74–61.89) 3 79
Change in morning PEF (l/min) 25.83 (20.48–31.17) 20 5308 19.66 (10.60–28.72) 5 1046
Change in evening PEF (l/min) 18.14 (13.23–23.06) 17 5048 10.38 (5.82–14.95) 4 1002
FEV1 (l)
 0.18 (0.13–0.23) 17 3465 0.12 (0.25–0.49) 2 70
Change in FEV1 (l)
 0.19 (0.16–0.23) 15 3423 0.18 (0.10–0.25) 5 1406
Day-time symptom scorey 0.32 (0.40 to 0.25) 15 3084 0.4 (0.9–0.1) 3 79
Night-time symptom scorey 0.41 (0.49 to 0.32) 10 2396 0.4 (0.9–0.1) 2 66
% Days without asthma symptoms 17.06 (13.93–20.19) 14 3700 12.7 (8.6–16.8) 4 789
% Nights without asthma awakenings 9.65 (5.67–13.64) 14 3140 8.1 (4.9–11.3) 4 789
Day-time relief SABA used (puffs) 0.80 (1.14 to 0.46) 9 2474 0.6 (1.7–0.5) 1 23
Night-time relief SABA used (puffs) 0.41 (0.60 to 0.23) 9 2478 0.1 (1.3–1.6) 1 23
Any drug-related adverse eventz 1.35 (1.03–1.77) 9 1444 Not estimable 0 0
Headachez 1.35 (1.01–1.81) 14 3982 1.80 (0.76–4.29) 2 452
Tremorz 1.69 (0.68–4.22) 6 1695 Not estimable 0 0
Risk of more than one major exacerbationz 0.78 (0.69–0.88) 27 7438 0.72 (0.52–1.00) 4 1020
Change in BHR (doubling doses) 0.48 (0.25–0.95) 9 1181 0.62 (0.30–0.95) 4 705
BHR, bronchial hyper-reactivity; ICS, inhaled corticosteroids; PEF, peak expiratory flow; SABA, short-acting b2-agonists.
WMD and 95% confidence interval (CI). Mean differences from individual trials are weighted and the inverse-variance method of meta-analysis used to obtain an overall mean
difference and CI.
ySMD with 95% CI. The overall difference in means from studies in which the outcome is measured in different units, divided by the pooled standard deviation of participants’
outcomes across the whole trial, is known as the standardized mean difference.
zOR and 95% CI using the Mantel–Haenszel method, which assumes a fixed-effect model of meta-analysis.
J.A
.E.
W
alters
et
al.
388
ARTICLE IN PRESS
 0  50  100
Review: Inhaled long acting beta agonists for stable chronic asthma
Comparison: 01 Studies with parallel group design
Outcome: 01 Peak expiratory flow: morning l/min
N N
Study 
or sub-category
LABA
  Mean (SD)
PLACEBO
   Mean (SD)
 WMD (fixed)
95% CI
01 Subjects using mixed cointerventions
  Dahl 1991 171 420.00 (0.00) 172 350.00 (0.00)
  Pearlman 1992 66 444.00 (102.00) 62 418.00 (83.00)
  D'Alonzo 1994 87 435.00 (112.00)                   90  421.00 (90.00)
  Busse 1998 261 392.50 (102.22) 231 373.70 (99.58)
  Ekstrom 1998 135 380.00 (95.00) 129 370.00 (117.00)
  Ekstrom Ringdal 1998 114 385.00 (89.00) 113 354.00 (100.00)
  Turner 1998 12 441.00 ( 82.00) 9 397.00 (89.00)
  Kemp 1999 176 470.00 (106.13) 176 435.00 (92.87)
  Wolfe 2000 165 420.00 (87.00) 167 408.00 (107.00)
  Bensch 2001 135 384.00 (101.00) 136 333.00 (108.40) 
Subtotal (95% CI) 1322  1285
  Test for heterogeneity: Chi² = 9.29, df=8 (P =0.32), I² =13.9%
  Test for overall effect: Z = 5.87 (P <0.00001) 
02 Subjects children <12 years
  Weinstein 1998 102 262.20 (72.70) 105 248.30 (88.10)
Subtotal (95% CI) 102 105
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
03 Subjects all using ICS (PG design)
  Pearlman 1992 21 448.00 (102.00) 20 417.00 (83.00)
  Pauwels HA 1997 215 420.00 (118.00) 214 383.00 (108.00)
  Pauwels LA 1997 210 412.00 (114.00) 213 385.00 (118.00)
  Langley 1998 25 395.00 (70.00) 24 361.00 (84.00)
  FitzGerald 1999 89 470.00 (90.00) 91 443.00 (86.00)
  Li 1999 13 490.00 (72.11) 16 410.00 (80.00)
Subtotal (95% CI) 573  578
  Test for heterogeneity: Chi² = 3.39, df=5 (P =0.64), I² =0%
  Test for over all effect: Z = 5.44 (P <0.00001) 
04 Subjects not using ICS (PG design)
  Boulet 1997 7 558.00 (0.00) 6 407.00 (0.00)
  Wronska 1998 13 450.00 (114.00) 9 358.00 (72.00)
  Roberts 1999 12 460.00 (93.00) 11 380.00 (128.00)
  Wallin 1999 21 544.00 (101.00) 22 536.00 (106.00)
Subtotal (95% CI) 53  48
Test for heterogeneity: Chi² = 3.30, df=2 (P =0.19), I² =39.3%
Test for overall effect: Z = 2.24 (P =0.02) 
Total (95% CI) 2050  2016
Test for heterogeneity: Chi² = 19.74, df = 18 (P = 0.35), I² =8.8%
Test for overall effect: Z = 8.18 (P <0.00001)
–100 –50
Favours PLACEBO Favours LABA
Figure 1 Effect size and pooled results for morning PEF in studies comparing LABAs with placebo.
Long-acting b2-agonists in asthma: an overview of Cochrane systematic reviews 389co-treatments, those taking ICS and also for
children. There was no statistically significant
effect on FEV1 for those not taking ICS, although
numbers were very small (n ¼ 70). A similar
difference was seen for the change in FEV1 during
treatment and, for this outcome, all sub-groups,
including those not taking ICS, were statistically
significant, probably as a result of larger numbers
of participants in the sub-groups (not on ICS:
n ¼ 1046).For the outcome measures related to sympto-
matic control and need for relief medication, the
positive outcomes for LABA were essentially similar
irrespective of sub-group. The scales used to
measure symptom scores ranged from 4 – 10 units
and, allowing for this, the overall standardized
mean difference (SMD) for day-time scores was
0.32 (95% CI 0.40 to 0.25) and night-time
scores was 0.41 (95% CI 0.49 to 0.32). This
equates to a difference of about 0.12 and 0.25 for
ARTICLE IN PRESS
Review: Inhaled long acting beta agonists for stable chronic asthma
Comparison: 01 Studies with parallel group design
Outcome: 05 Change in PEF morning (l/min)
Study
or sub-category
LABA
  Mean (SD)
PLACEBO
  Mean (SD)N N
–100  –50  0  50  100
Favours PLACEBO Favours LABA
01 Subjects using mixed cointerventions
  Dahl 1991 131 40.00 (0.00) 129 –4.00 (0.00)
  Pearlman 1992 66 26.00 (49.00) 62  9.00 (50.00)
  D'Alonzo 1994 87 25.00( 58.00) 90 –2.00 (47.00)
  Schreurs 1996 49 33.00 (41.00) 51 –3.00 (30.00)
  Adinoff  1998 117 32.30 (0.00) 121  4.90 (0.00)
  Busse 1998 261 53.70 (50.94) 272 20.20 (44.01)
  Kemp Wolfe 1998 149 33.00 (45.20) 12 5.00 (45.60)
  Lockey 1999 240 47.00 (61.97) 234 2.00 (61.19)
Subtotal (95% CI) 1100  971
Test for heterogeneity: Chi² = 8.61, df = 5 (P = 0.13), I² = 41.9%
Test for overall effect: Z = 8.75 (P < 0.00001)
02 Subjects children <12 years
  Simons 1997 80 41.00 (0.00) 80 25.00 (0.00)
  Verberne 1998                       60  41.80 (34.85) 57 27.30 (43.41)
  Von Berg 1998 199 34.00 (42.32) 188 17.00 (41.13)
  Weinstein 1998 102 25.10 (25.61) 105 10.10 (25.60)
  Bensch 2002 171 40.00 (0.00) 176 21.00 (0.00)
Subtotal (95% CI) 612  606
Test for heterogeneity: Chi² = 0.16, df = 2 (P = 0.92), I² = 0% 
Test for overall effect: Z = 6.13 (P < 0.00001)
03 Subjects all using ICS (PG design)
  Jones 1994 120 16.00 (0.00) 60 10.00 (0.00)
  Boyd 1995  47 45.00 (41.00) 50 23.00 (45.00)
  Langton Hewer 1995 11 26.00 (49.00) 12 –35.00 (63.00)
  Pearlman A 1999 25 57.00( 50.00) 23 10.00 (38.42) 
  Pearlman H 1999 21 32.00 (59.60) 23 25.00 (43.20)
  Kavuru A 2000  87 52.50 (49.44) 85 17.30 (40.57) 
  Shapiro A 2000 81 53.50 (50.40) 81 15.20 (41.40)
Subtotal (95% CI) 392  334
Test for heterogeneity: Chi² = 7.53, df = 5 (P = 0.18), I² = 33.6% 
Test for overall effect: Z = 6.43 (P < 0.00001)
04 Subjects not using ICS (PG design)
  Jones 1994 162 22.00 (0.00)  85 3.00 (0.00)
  Nathan 1999                        128  36.00 (56.50)                   129  12.00 (56.80)
  Pearlman B 1999 21 41.00 (55.00) 23 –1.00 (33.60)
  Rosenthal 1999 202 26.20 (35.53) 206 5.30( 28.71)
  Kavuru B 2000 77 –1.70 (42.66) 86 –23.70 (42.12)
  Shapiro B 2000 84 –11.60 (47.70) 90 –14.10 (37.00)
Subtotal (95% CI) 674  619
Test for heterogeneity: Chi² = 10.19, df = 4 (P = 0.04), I² = 60.8%
Test for overall effect: Z = 4.25 (P < 0.0001)
Total (95% CI) 2778   2530
Test for heterogeneity: Chi² = 60.61, df = 19 (P < 0.00001), I² = 68.7%
Test for overall effect: Z = 9.47 (P < 0.00001)
WMD (random)
95% CI
Figure 2 Effect size and pooled results for change in morning PEF in studies comparing LABAs with placebo.
J.A.E. Walters et al.390day-time and night-time, respectively, on a six-
point scale, favouring LABA treatment.
When people taking ICS regularly are compared
with people who are not, the results show little
difference, with all results in favour of LABA. This is
especially so where the number of participants was
reasonably robust (i.e. day- and night-time symp-tom scores and the percentage increase in days and
nights without asthma symptoms).
In addition to the expected drug-related adverse
events due to known pharmacological effects of
LABA (i.e. headache, tremor muscle, cramps and
palpitations), the review analysed data on asthma
‘‘exacerbations’’; however, they were defined in
ARTICLE IN PRESS
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were analysed together for any drug-related
adverse effect, the odds ratio (OR) was elevated
at 1.35 (95% CI 1.03–1.77) in nine studies with 2823
participants. The only individual adverse effect for
which there was a significantly increased risk was
headache, OR 1.35 (95% CI 1.01–1.81).
Twenty-seven parallel-group studies, with 7438
individual participants, reported data on exacer-
bations. In 15 studies with adult participants, a
‘‘major’’ exacerbation of asthma was defined as
worsening of asthma symptoms requiring treatment
in addition to the study drug and usual rescue
inhaled SABA agent. In seven studies, the definition
was not given or was less precise. Overall, there
was a significant reduction in the risk of experien-
cing at least one major exacerbation during the
study period in the LABA group compared with
placebo, OR 0.78 (95% CI 0.69–0.88), with no
significant heterogeneity (I2 29.4%) (i.e. the chance
of an exacerbation of asthma was decreased by
about 25% overall). When the analysis was confined
to 15 studies (n ¼ 3934), with a uniform defini-
tion of a major exacerbation, the effect was
even larger, OR 0.66 (95% CI 0.56–0.78), and
the risk difference (RD) 0.04 (95% CI 0.05
to 0.02).
Interestingly, in four studies with a total of 1020
participants not using ICS, there was a very similar
reduction in risk of a major exacerbation, OR 0.72
(95% CI 0.52–1.0), but the difference was not
statistically significant. In two studies of 6 months’
duration31,32 using participants who had not been
taking ICS during the previous 6 months, the
difference in exacerbation risk between groups
for steroid-naı¨ve participants was not significant,
OR 0.83 (95% CI 0.53–1.29). In both studies, around
13% of participants treated with LABA experienced
at least one major exacerbation. In two studies of 3
months’ duration,33,34 using participants who had
been taking ICS for at least 3 months but then
stopped at randomization, there was a reduction in
exacerbations, OR 0.58 (95% CI 0.36–0.98), RD
0.09 (95% CI 0.18 to 0.01). However, in these
two studies of previous ICS users, 38% and 44%,
respectively, of LABA-treated participants were
withdrawn during the 3 months because of worsen-
ing asthma. In addition, the difference between
the three regular background treatment sub-groups
(ICS use, no ICS use and mixed co-interventions) for
the outcome ‘‘risk of an exacerbation’’ using the
Peto OR is significant (w2 14.3, df 2), suggesting that
the result of meta-analysis needs to be interpreted
with some caution.
The sub-group result in children under 12 years of
age (from five studies that reported on exacerba-tions) showed a small and non-significant increase
in risk, OR 1.2 (CI 0.92–1.55) with LABA treatment.
Despite previous concerns, in an analysis of eight
studies lasting at least 6 weeks in which change in
bronchial hyper-reactivity (BHR) was measured as
an outcome, there was a small but significant
lessening of BHR in favour of LABA use. Interest-
ingly, in the sub-group analysis, the positive effect
on BHR was clearest for those taking ICS, although
this may reflect increased power, because of the
greater numbers in this sub-group analysis (350 of
the total 600).
The following conclusions were drawn from this
large review based on a broad range of studies
across the asthma spectrum: (1) overall, the data
gave reassuring evidence for the effectiveness and
safety of LABA used regularly in chronic asthma,
compared with placebo in randomized-control
trials; (2) there was no evidence that underlying
control of asthma deteriorated with regular use of
LABA and, indeed, overall there was a decrease in
exacerbation rates; (3) the evidence supports the
use of LABA in addition to ICS as emphasized in
current guidelines; (4) the data from the patients
included in these studies also suggest that regular
LABAs have some positive effects in patients not
using regular ICS but without increasing the risk of
exacerbations or BHR.Regular treatment with long-acting
b-agonists versus daily regular treatment
with short-acting b-agonists in adults and
children with stable asthma
In this Cochrane review,26 most of the 31 included
studies were in mild-to-moderate asthma, with
participants in all but one study taking other
regular co-interventions. In 24 of these 30 studies,
at least 50% of participants were using regular ICS
(Table 2). Again, the primary outcome was asthma
control (Table 4). LABAs were significantly better
than SABA for a variety of lung function measure-
ments, including morning and evening PEF, and had
significantly lower scores for day and night-time
asthma symptoms and percentage of days and
nights without symptoms. LABAs were also asso-
ciated with a significantly lower use of rescue
medication during the day and night.
The risk of exacerbations was not different
between the two types of agent, but most studies
were of short duration, which limited the power to
test for, and assess the relevance of, such differ-
ences.
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Table 5 Effect of LABA versus theophyllines for maintenance treatment of asthma.
Outcome Overall difference Studies Participants
Morning PEF (l/min) 37.20 (7.65–82.05) 1 112
Evening PEF (l/min) 39.70 (5.00–84.40) 1 112
FEV1 (% predicted)
 9.00 (7.80–10.20) 1 96
Day-time symptom score 0.20 (0.49–0.09) 1 40
Night-time symptom score 0.10 (0.37–0.17) 1 45
Any drug-related adverse eventy 0.44 (0.30–0.63) 5 807
Central nervous system adverse eventy 0.50 (0.29–0.86) 4 527
Gastrointestinal adverse eventy 0.30 (0.17–0.55) 4 527
WMD and 95% CI. Mean differences from individual trials are weighted and the inverse-variance method of meta-analysis
used to obtain an overall mean difference and CI.
yRR and 95% CI using the Mantel–Haenszel method, which assumes a fixed-effect model of meta-analysis.
Table 4 Effects of LABA versus SABA treatment in adults and children.
Outcome Difference Studies Participants
Morning PEF (l/min) 32.93 (24.8–41.4) 8 1881
Evening PEF (l/min) 25.62 (17.98–32.27) 8 1878
Change in morning PEF (l/min) 27.38 (22.98–31.77) 6 2117
Change in evening PEF (l/min) 11.94 (7.99–15.90) 6 1991
FEV1 (l)
 0.22 (0.14–0.31) 8 1397
Day-time symptom score 0.15 (0.23 to 0.06) 3 678
Night-time symptom score 0.21 (0.31 to 0.10) 3 701
% Days without asthma symptoms 10.34 (1.80–18.88) 2 307
% Nights without asthma awakenings 12.12 (7.80–16.43) 3 606
Day-time relief SABA used (puffs) 0.33 (0.16 to 0.5) 4 1002
Night-time relief SABA used (puffs) 0.31 (0.19 to 0.43) 4 1002
Overall quality of lifey 0.54 (0.39–0.69) 2 727
Any drug-related adverse eventz 1.13 (0.80–1.59) 5 953
Headachez 1.28 (1.02–1.61) 13 3737
Tremorz 0.68 (0.43–1.07) 11 3780
Risk of more than one major exacerbationz 0.90 (0.78–1.03) 14 28,814
Deathsz 3.00 (0.67–13.41) 1 25,180
LABA, long-acting b2-agonists; SABA, short-acting b2-agonists; PEF, peak expiratory flow.
WMD and 95% CI. Mean differences from individual trials are weighted and the inverse-variance method of meta-analysis
used to obtain an overall mean difference and CI.
ySMD with 95% CI. The overall difference in means from studies in which the outcome is measured in different units, divided
by the pooled standard deviation of participants’ outcomes across the whole trial, is known as the standardized mean
difference.
zOR and 95% CI using the Mantel–Haenszel method, which assumes a fixed-effect model of meta-analysis.
J.A.E. Walters et al.392The following conclusions were drawn from this
relatively large review: (1) LABAs have advantages
in clinical outcomes when used regularly over the
effects of regular inhaled SABA; (2) the increased
cost of treatment, if more LABAs are prescribed,
has implications for medical costs, which will only
be partially offset by reduced symptom-directed
use of SABA.Long-acting b-agonists versus
theophylline for maintenance treatment
of asthmaIn this Cochrane review,27 12 studies were included,
involving 1329 participants. Nine studies used
salmeterol, two used eformoterol and one used
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included using ICS, with an average of 60% of
participants in these studies using regular ICS,
whereas in three studies they were not permitted.
Unfortunately, because of lack of appropriate
data, only limited meta-analyses were possible, but
a number of findings were drawn from the review
(Table 5): (1) LABA and theophylline are both
effective in increasing lung function in asthma
but, in five individual studies, LABA increased PEF
significantly more than theophylline; (2) in six
studies, no significant difference was found
between LABA and theophylline on the increase
from baseline in FEV1 and, in two studies, salme-
terol was significantly more effective; (3) LABA
gave more symptom-free nights than theophylline
and less need for rescue SABA medication, but
these data come from individual studies as pooling
was not possible because of reporting differences;
(4) LABA use significantly reduced the risk of
adverse events associated with theophylline use,
with an overall relative risk (RR) of 0.44 (95% CI
0.30–0.63). The reduction in risk was significant for
central nervous system side-effects such as head-
ache, RR 0.50 (95% CI 0.29–0.86) and gastrointest-
inal side-effects, RR 0.30 (95% CI 0.17–0.55).
Despite this, there was a non-significant difference
between treatments for withdrawals.
The authors concluded that LABAs are as effec-
tive as theophyllines in reducing asthma symptoms
and have fewer adverse effects.
These reviews confirm the effectiveness of LABA
in the management of chronic asthma.Discussion
In general, the reviews support international
management guidelines in their current placement
of LABA (i.e. as additional therapy when asthma is
inadequately controlled by ICS at moderate dose).
However, several individual studies, across a wide
range of starting ICS doses, have shown that LABAs
are able to keep the dose of ICS needed to control
asthma below the threshold for systemic absorp-
tion, thus decreasing the potential for long-term
systemic adverse effects.35,36 These data have yet
to be combined in a systematic review or included
in management guidelines.
In addition to supporting established asthma
management guidelines, we are interested in how
these reviews help clinicians and patients in the
‘‘real’’ world, with its constraints and compro-
mises. We know from extensive analysis of ther-
apeutic practice in the community5 that mostasthma is mild and uncomplicated by major
exacerbations; patients may still continue to have
frequent symptoms; and, in spite of their symp-
toms, most patients do not use ICS as prescribed.
Data in Australia suggest that about a third of
patients with asthma are prescribed ICS, but only a
third of them actually use them regularly—many on
the basis of negative attitudes towards their
medication.5 These considerations raise the ques-
tion of whether, given their symptom levels and
lack of use of ICS, such patients might be better off
using regular LABA than frequent SABA.
A published systemic review37 has shown that the
regular use of inhaled SABA is not associated with a
clinically meaningful deleterious effect on the main
indicators of asthma control. Neither is there any
major beneficial effect, beyond that achieved by
their ‘‘as needed’’ use. The current reviews would
indicate that if frequent airway b-receptor stimu-
lation is required, then a long-acting agent (LABA)
has distinct advantages over short-acting agents.
What then of the residual worries inherent in
‘‘the continuing b-agonist debate’’? Two large post-
marketing phase IV studies with salmeterol have
been conducted, and need to be mentioned before
finally trying to answer that question: the Serevent
Nationwide Surveillance Study (SNSS)38 in a
general-practice setting in the UK in the early
1990s and the Salmeterol Multi-centre Asthma
Research Trial (SMART) initiated in the USA by GSK
in 1996.39
The important points to emerge were as follows:
(1) asthma mortality is related to severity of
disease and reflected in high levels of use of relief
bronchodilator medication; (2) underuse of ICSs in
severe asthmatics is dangerous; (3) many patients
classified as ‘‘mild’’ are still using substantial
amounts of relief medication [1.2 canisters/month
(i.e. 6–8 puffs/24 h in SNSS)]; and (4) LABAs are not
a substitute for ICSs and should not be initiated in
patients with significantly worsening or acutely
deteriorating asthma.
Worries have reasonably been expressed about
mortality rates in these studies. The SNSS had a
three-fold increase in deaths in the salmeterol
group compared with the placebo group, but the
difference was not significant as the rate of
‘‘events’’ was low and not different from what
was expected. There was no pattern of severe
asthma events occurring in the salmeterol group to
suggest some systematic danger signal. Indeed,
there were significantly fewer dropouts due to
asthma worsenings in the salmeterol group. The
SMART study was stopped prematurely, but has not
been published. Again, there was concern about
excess mortality in the LABA limb. This seems to
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participants who had more severe asthma at entry
and were likely to have been undertreated with
ICS.
What is uncertain from these studies is the level
of asthma severity or use of SABA relief medication
that should mandate the use of ICS. Current asthma
management guidelines are imprecise. GINA guide-
lines state that ‘‘inhaled glucocorticosteroids are
the most effective controller therapy, and are
therefore recommended treatment for persistent
asthma at any step of severity’’.1 The Australian
NAC guidelines2 state that ‘‘symptoms should be
relieved with intensive initial therapy (with ICS)
and then minimum maintenance doses (of ICS) used
to maintain good symptom control, minimize
side-effects and maximize adherence’’, without
specifying at what level of symptoms ICS should
be introduced. UK guidelines state that ‘‘though
the threshold has not been firmly established,
there is evidence for their (ICS) introduction if
SABA are used more than two or three times a
day’’.3
The dilemma is exacerbated because guidelines
are not well implemented in practice. To what
extent should energy be directed solely at better
implementation, with increased prescribing of ICS,
or should we expend efforts on better recognition
of patients with minimal risk of life-threatening
events who could be given LABA safely in the
absence of ICS? Further research on this is needed;
until then, it is sensible that our focus is on better
and more generalized implementation of current
guidelines.
The enduring worry is that such an alternative
approach could delay the use of ICS in patients who
need them and, by so doing, put such patients at
risk. We would certainly not want to encourage
inadequate assessment and management of asth-
ma, nor discourage use of ICS where this is
appropriate. It is possible, however, that there is
a group of mild relatively stable patients, not using
ICS, who may be better off using LABA than repeat
dosing with SABA.
Practice points
 LABAs are better than placebo in improving
lung function, symptom scores and use of
relief medication.
 LABAs are better than regular SABA.
 LABA do not worsen BHR.
 LABAs reduce exacerbation rates in adults.
 LABAs are better than theophyllines and
have fewer side-effects.Research directions
 Can we define a group of patients who are
using SABA frequently in whom it would be
safe to use LABA without ICS?
 What are the preferences of patients in this
group?
 What are the safety and efficacy of LABA
versus low-dose ICS in mild asthma?
 When should ICS definitely be introduced?
 What are the optimum combinations of LABA
and ICS to maximize asthma control and
minimize adverse effects?References
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